Table 2.
Histopathologic data on kidney biopsies from patients with COVID-19-associated nephropathy
| Parameter | Total | No progression (n = 29) | Progression to ESKD (n = 14) | P value |
|---|---|---|---|---|
| Global glomerulosclerosis (n = 43) | 34.1 ± 25.9% | 25.0 ± 23.2% | 52.9 ± 21.3% | |
| Interstitial fibrosis+Tubular atrophy (n = 43) | ||||
| Mild | 14/43 | 13/29 | 1/14 | 0.017 |
| Moderate | 15/43 | 10/29 | 5/14 | 1.000 |
| Severe | 14/43 | 6/29 | 8/14 | 0.034 |
| Arteriosclerosis (n = 38 with available data) | ||||
| None | 6/38 (15.8%) | 6/25 | 0/13 | 0.076 |
| Mild | 9/38 (23.7%) | 6/25 | 3/13 | 1.000 |
| Moderate | 8/38 (21.1%) | 6/25 | 2/13 | 1.000 |
| Severe | 15/38 (39.5%) | 7/25 | 8/13 | 0.079 |
| Arteriolar hyalinosis (n = 39 with data) | ||||
| None | 16/39 | 14/26 | 2/13 | 0.037 |
| Mild | 9/39 | 5/26 | 4/13 | 0.45 |
| Moderate | 5/39 | 4/26 | 1/136/13 | 0.65 |
| Severe | 9/39 | 3/26 | 0.039 |